Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
Clinical trial NCT06107738 · RECRUITING
Trial details
- NCT number
- NCT06107738
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-21
- Primary completion
- 2027-12-31
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.